Corrigendum to “Improved clinical outcomes with low-dose anti-CTLA-4 (Nurulimab) plus anti-PD-1 (Prolgolimab) vs. anti-PD-1 monotherapy in advanced cutaneous melanoma: Results from the phase III OCTAVA trial” [Eur J Cancer. 227 (2025) 115674] (European Journal of Cancer (2025) 227, (S0959804925004563), (10.1016/j.ejca.2025.115674))

Demidov, L., Samoylenko, I., Kharkevich, G., Orlova, K., Moiseenko, V., Utyashev, I., Stroyakovskiy, D., Kozlov, V., Zimina, A., Mochalova, A., Demidova, S., Lyadova, M., Kutkovich, A., Skopin, P., Kovalenko, N., Safina, S., Volkov, V., Semiletova, Y., Vaschenko, V., Kislov, N. & 30 others, Poltoratskiy, A., Shumskaya, I., Kolomiets, S., Sobolev, A., Belogortsev, I., Odintsova, S., Rastogi, S., Andabekov, T., Penkov, K., Semenova, A., Obukhov, A., Belyakovsky, V., Yurchenkov, A., Gladkov, O., Neve, R., Falaleeva, N., Poddubskaya, E., Vaibhav, A., Kirtbaya, D., Chapko, Y., Smagina, M., Fadeeva, N., Sorokina, I., Mikhailova, E., Lin’kova, Y., Zinkina-Orikhan, A., Lutskii, A., Gabidullin, R., Rzaev, R. & Kryukov, F., 30 Aug 2025, In: European Journal of Cancer. 228

Research output: Contribution to journal › Comment/debate › peer-review

现阶段俄罗斯与欧盟经贸关系 的问题和前景 阿列克桑德拉·莫恰洛娃 谢尔盖·苏特林

Сутырин, С. Ф. & Мочалова, А. И., Feb 2025, In: Russian Studies. 251, 1, p. 145-164

Research output: Contribution to journal › Article › peer-review